Osteomalacia & Rickets

1. Clinical Overview

Osteomalacia and rickets represent a spectrum of metabolic bone disorders characterised by defective mineralisation of bone matrix (osteoid), resulting in structurally weak, undermineralised bones. The distinction between these conditions is purely temporal: rickets occurs in children before epiphyseal closure, affecting both cortical and trabecular bone as well as the growth plates, whilst osteomalacia manifests in adults after growth plate fusion, affecting only the bone matrix. Both conditions share identical pathophysiology—inadequate availability of calcium and phosphate for hydroxyapatite crystal deposition on osteoid.

Despite dramatic reductions following vitamin D fortification programmes in the mid-20th century, these conditions have re-emerged as significant public health concerns in developed nations. A 2016 systematic review estimated vitamin D deficiency (the primary cause) affects approximately 1 billion people worldwide, with prevalence rates of 30-60% in adults and 50-70% in children in European countries, particularly among migrants from South Asia, the Middle East, and Africa. [1,2] The clinical spectrum ranges from subtle biochemical abnormalities and vague musculoskeletal complaints to devastating skeletal deformities, pathological fractures, and life-threatening hypocalcaemic complications including seizures, tetany, and cardiomyopathy.

The condition is both preventable and reversible with appropriate treatment. Early recognition and intervention can prevent permanent skeletal deformities in children and rapidly alleviate bone pain and muscle weakness in adults. The key to diagnosis lies in maintaining clinical suspicion, particularly in at-risk populations, and recognising the characteristic biochemical triad of low/normal calcium, low phosphate, and elevated alkaline phosphatase. [3,4]

Clinical Pearls

Proximal Myopathy—The Pathognomonic Yet Overlooked Sign: One of the most characteristic features of osteomalacia is proximal muscle weakness, manifesting as difficulty rising from a chair, climbing stairs, or brushing hair. This "waddling gait" results from hypophosphataemia-induced ATP depletion in muscle cells, not primary muscle pathology. It is one of the few reversible causes of proximal myopathy and resolves within weeks of vitamin D replacement—a diagnostic and therapeutic triumph. [5]

Looser's Zones (Pseudofractures)—The Radiological Hallmark: These pathognomonic radiolucent lines appear perpendicular to the cortical bone surface, representing unmineralised osteoid at sites of repetitive mechanical stress where nutrient arteries penetrate the cortex. Classic locations include the medial femoral neck, pubic rami, ribs, clavicles, and scapulae. They are bilateral, symmetrical, and represent impending complete fractures. On bone scintigraphy, they demonstrate intense uptake ("hot spots"). [6,7]

The Alfacalcidol Imperative in Renal Disease: A critical prescribing error is treating renal osteodystrophy with standard cholecalciferol (vitamin D3) or ergocalciferol (D2). These require 1-alpha-hydroxylation by the kidney to become active. In chronic kidney disease (CKD) stage 4-5, this enzymatic step is lost. Alfacalcidol or calcitriol must be prescribed instead, as these are already activated and bypass the failing kidney. Over-the-counter supplements and standard vitamin D preparations are ineffective in advanced CKD. [8,9]

Nutritional Rickets Is Not Just a Disease of Poverty: Modern rickets occurs predominantly in apparently well-nourished children in affluent societies, driven by sun avoidance (skin cancer awareness, sunscreen use), cultural practices (modest dress), exclusive breastfeeding without supplementation, and migration of dark-skinned populations to high latitudes. It is a disease of cultural transition, not malnutrition. [10,11]

The "Rickety Rosary" and Harrison's Sulcus: These classic paediatric signs reflect fundamental biomechanical consequences of soft bones. The rickety rosary represents expansion of the costochondral junctions (resembling rosary beads) due to overgrowth of unmineralised cartilage. Harrison's sulcus is a horizontal indentation along the lower chest wall corresponding to diaphragm insertion, where the softened ribs are "pulled in" with each breath. Both indicate severe, prolonged disease. [12]

---

2. Epidemiology

Global Burden and Re-emergence

Once considered a disease of historical interest following vitamin D fortification of milk and infant formulas in the 1930s-1950s, osteomalacia and rickets have re-emerged as major public health issues globally. The WHO estimates that vitamin D deficiency affects approximately 1 billion people worldwide, with the highest rates in South Asia, the Middle East, and among migrant populations in Northern Europe and North America. [1,13]

Demographics and Risk Factors

Age Distribution:

• Rickets: Peak incidence 6-24 months (period of rapid bone growth); second peak in adolescence during growth spurts
• Osteomalacia: Bimodal distribution—young adults in high-risk groups and elderly > 65 years

Sex: Females are disproportionately affected (2-3:1 ratio) due to cultural dress practices, pregnancy/lactation calcium demands, and higher rates of housebound status in elderly. [18]

Ethnicity: The most powerful risk factor is dark skin pigmentation (melanin absorbs UVB radiation, reducing vitamin D synthesis). Risk is magnified when dark-skinned populations migrate to high latitudes:

• South Asian populations in UK: 50-fold increased risk compared to native population
• African/Afro-Caribbean populations: 20-fold increased risk
• Middle Eastern populations: 30-fold increased risk [14,16]

High-Risk Populations

Dietary and Lifestyle Factors:

1. Strict veganism without supplementation (vitamin D is primarily found in animal products: oily fish, egg yolks, fortified dairy)
2. Exclusive breastfeeding beyond 6 months without vitamin D supplementation (breast milk contains only 25 IU/L, insufficient to prevent deficiency) [19]
3. Cultural/religious dress practices covering most skin (hijab, niqab, burqa)
4. Sun avoidance behaviours: Excessive sunscreen use (SPF > 30 blocks > 95% of vitamin D synthesis), indoor lifestyle, shift workers
5. Institutionalised/housebound individuals: Nursing home residents, prisoners, psychiatric inpatients

Medical Risk Factors:

1. Malabsorption syndromes:
   • Coeliac disease (30-50% have vitamin D deficiency) [20]
   • Inflammatory bowel disease (Crohn's disease > ulcerative colitis)
   • Post-bariatric surgery (especially Roux-en-Y gastric bypass)
   • Chronic pancreatitis/exocrine pancreatic insufficiency
   • Bile acid malabsorption/cholestatic liver disease
2. Chronic kidney disease: CKD stage 3-5 (GFR less than 60 mL/min)—impaired 1-alpha-hydroxylation
3. Liver disease: Severe cirrhosis impairs 25-hydroxylation
4. Drug-induced:
   • Anticonvulsants (phenytoin, carbamazepine, phenobarbital—induce CYP450, accelerating vitamin D catabolism)
   • Rifampicin (similar CYP450 induction)
   • Antiretrovirals (efavirenz)
   • Long-term glucocorticoids [21]

Inherited Disorders (Rare):

1. X-linked hypophosphataemic rickets (XLH): Most common inherited form (1:20,000), caused by PHEX gene mutations leading to excess FGF23 and renal phosphate wasting—"vitamin D-resistant rickets"
2. Hereditary hypophosphataemic rickets with hypercalciuria (HHRH): Autosomal recessive, mutations in SLC34A3
3. Vitamin D-dependent rickets type 1 (VDDR1): Deficiency of 1-alpha-hydroxylase (autosomal recessive)
4. Vitamin D-dependent rickets type 2 (VDDR2): Vitamin D receptor mutations (autosomal recessive)—patients require massive doses of calcitriol [22]

Temporal Trends

In the UK, hospital admissions for rickets increased 5-fold between 1995 and 2011, predominantly affecting South Asian and Afro-Caribbean children. [14] Similar trends are observed in Germany, Denmark, and Australia, driven by migration patterns and changing cultural practices around sun exposure. [23]

---

3. Aetiology and Pathophysiology

The Vitamin D Endocrine Axis

Vitamin D functions as a steroid hormone regulating calcium and phosphate homeostasis. Understanding its metabolic pathway is essential for rational treatment:

Step 1: Synthesis/Intake

• Cutaneous synthesis: UVB radiation (290-315 nm) converts 7-dehydrocholesterol in the epidermis to cholecalciferol (vitamin D3)—accounts for 80-90% of vitamin D in sun-exposed individuals
• Dietary intake: Vitamin D3 (animal sources) or ergocalciferol/D2 (plant sources, less bioavailable)—only 10-20% of vitamin D in typical diets

Step 2: Hepatic Activation

• Cholecalciferol is hydroxylated in the liver by 25-hydroxylase (CYP2R1) to form 25-hydroxyvitamin D [25(OH)D]—the major circulating form and best biomarker of vitamin D status (half-life ~3 weeks)

Step 3: Renal Activation

• 25(OH)D undergoes further hydroxylation in the proximal renal tubules by 1-alpha-hydroxylase (CYP27B1) to form 1,25-dihydroxyvitamin D [1,25(OH)2D, calcitriol]—the active hormonal form
• This step is tightly regulated by:
  • PTH (stimulates 1-alpha-hydroxylase)
  • FGF23 (inhibits 1-alpha-hydroxylase, stimulates 24-hydroxylase for degradation)
  • Hypocalcaemia and hypophosphataemia (stimulate 1-alpha-hydroxylase)

Step 4: Biological Actions

Calcitriol binds to nuclear vitamin D receptors (VDR) in target tissues:

1. Intestine: Increases transcription of calcium-binding proteins (calbindins), calcium channels (TRPV6), and phosphate transporters → enhanced calcium and phosphate absorption
2. Bone: Promotes osteoblast differentiation and mineralisation; paradoxically also stimulates osteoclast activity (mobilising calcium in deficiency states)
3. Kidney: Increases distal tubular calcium reabsorption
4. Parathyroid glands: Negative feedback—suppresses PTH secretion [24,25]

Pathophysiology of Defective Mineralisation

Normal bone mineralisation requires:

1. Adequate osteoid (collagen matrix) produced by osteoblasts
2. Sufficient calcium and phosphate to form hydroxyapatite crystals [Ca10(PO4)6(OH)2]
3. Optimal pH and enzyme activity (alkaline phosphatase)

In osteomalacia/rickets, vitamin D deficiency creates a cascade of events:

Stage 1: Vitamin D Insufficiency

• ↓ Calcitriol → ↓ Intestinal Ca/PO4 absorption
• ↓ Serum calcium (ionised calcium falls first, often before total calcium)

Stage 2: Compensatory Response (Secondary Hyperparathyroidism)

• Parathyroid glands sense hypocalcaemia via calcium-sensing receptors (CaSR)
• ↑ PTH secretion attempts to restore normocalcaemia by:
  1. ↑ Bone resorption (osteoclast activation)—releases calcium from skeleton
  2. ↑ Renal calcium reabsorption (distal tubule)
  3. ↑ Renal phosphate excretion (proximal tubule phosphaturia)—this is maladaptive, as phosphate is needed for mineralisation
  4. ↑ 1-alpha-hydroxylase activity (attempting to generate more calcitriol from diminishing 25(OH)D stores)

Stage 3: Mineralisation Failure

• Despite elevated ALP (reflecting osteoblast activity), the calcium-phosphate product (Ca × PO4) falls below the critical threshold (~3.0 mmol²/L²) required for hydroxyapatite precipitation
• Osteoid continues to be laid down by osteoblasts but cannot mineralise
• Bone becomes progressively weaker—soft, pliable, prone to deformity and fracture

Stage 4: Skeletal Consequences

In children (Rickets):

• Growth plate disruption: Failure of mineralisation at the zone of provisional calcification → widening, irregularity, cupping of metaphyses
• Skeletal deformity: Softened long bones bow under weight-bearing (genu varum, genu valgum, anterior bowing of tibiae)
• Delayed growth: Linear growth impairment, short stature
• Cranial changes: Delayed fontanelle closure, craniotabes (skull softening), frontal bossing

In adults (Osteomalacia):

• Bone pain: Due to periosteal elevation, microfractures in undermineralised bone
• Pseudofractures (Looser's zones): Incomplete stress fractures at sites of vascular penetration
• Complete fractures: Increased fragility fracture risk (vertebral, hip, wrist)
• Bone deformity: Kyphosis, loss of height, protrusio acetabuli [3,4,26]

Stage 5: Extraskeletal Manifestations

Neuromuscular:

• Hypocalcaemia-induced neuromuscular irritability: Tetany, carpopedal spasm, laryngospasm, seizures (severe cases)
• Myopathy: Hypophosphataemia impairs ATP synthesis → proximal muscle weakness, myalgia

Cardiovascular:

• Cardiomyopathy: Severe hypocalcaemia impairs excitation-contraction coupling → dilated cardiomyopathy, heart failure, prolonged QT interval

Immunological:

• Vitamin D deficiency impairs innate immunity → increased susceptibility to respiratory infections (particularly tuberculosis historically) [27]

Causes of Osteomalacia/Rickets

1. Vitamin D Deficiency (> 90% of cases)

Inadequate Synthesis:

• Insufficient sun exposure (latitude > 40°, winter months, cultural practices, housebound status)
• Dark skin pigmentation (melanin absorption of UVB)
• Sunscreen use (SPF 30 reduces synthesis by > 95%)

Inadequate Intake:

• Vegan diets without supplementation
• Absence of fortified foods
• Exclusive breastfeeding without infant supplementation

2. Vitamin D Malabsorption

Gastrointestinal Disorders:

• Coeliac disease (30-50% prevalence of deficiency) [20]
• Inflammatory bowel disease (Crohn's disease > UC)
• Post-gastrectomy/bariatric surgery (especially Roux-en-Y bypass)
• Small bowel resection/short bowel syndrome
• Chronic pancreatitis/pancreatic insufficiency
• Biliary obstruction/cholestatic liver disease
• Bacterial overgrowth

3. Impaired Vitamin D Activation

Hepatic Dysfunction:

• Severe cirrhosis impairs 25-hydroxylation
• Biliary atresia/neonatal cholestasis

Renal Dysfunction:

• CKD stage 3-5: Impaired 1-alpha-hydroxylation
• Fanconi syndrome: Renal tubular dysfunction with phosphate wasting
• Renal tubular acidosis (type 1 and 2)
• Tumour-induced osteomalacia: FGF23-secreting mesenchymal tumours suppress 1-alpha-hydroxylase [28]

Drug-Induced Catabolism:

• Anticonvulsants (phenytoin, carbamazepine, phenobarbital): Induce CYP450 enzymes, accelerating vitamin D degradation
• Rifampicin (similar mechanism)
• Antiretrovirals (efavirenz) [21]

4. Hypophosphataemic Disorders

X-Linked Hypophosphataemic Rickets (XLH):

• Most common inherited rickets (1:20,000)
• PHEX gene mutation → ↑ FGF23 → renal phosphate wasting
• Clinical: Short stature, bowing, dental abscesses; normal calcium, very low phosphate
• Treatment: Oral phosphate + calcitriol (not standard vitamin D) [22]

Other Phosphate-Wasting Disorders:

• Autosomal dominant/recessive hypophosphataemic rickets (FGF23 mutations)
• Tumour-induced osteomalacia (oncogenic osteomalacia): Mesenchymal tumours secreting FGF23—cured by tumour resection [28]
• Hereditary hypophosphataemic rickets with hypercalciuria (HHRH)

5. Inherited Vitamin D Metabolism Defects (Very Rare)

Vitamin D-Dependent Rickets Type 1 (VDDR1):

• Autosomal recessive mutation in CYP27B1 (1-alpha-hydroxylase)
• Presents in infancy with severe rickets despite adequate vitamin D stores
• Treatment: Calcitriol (bypasses defective enzyme)

Vitamin D-Dependent Rickets Type 2 (VDDR2):

• Autosomal recessive mutation in vitamin D receptor (VDR)
• Presents with severe rickets + alopecia totalis (pathognomonic)
• Extremely high calcitriol levels (↑↑ 1,25(OH)2D) but end-organ resistance
• Treatment: Supraphysiological doses of calcitriol + calcium infusions [22]

6. Chronic Hypophosphataemia from Other Causes

• Chronic ingestion of phosphate binders (antacids containing aluminium hydroxide)
• Poorly controlled diabetes mellitus (renal phosphate wasting)
• Prolonged total parenteral nutrition (TPN) without phosphate supplementation

Exam Detail: ### Molecular Mechanisms: FGF23-Klotho Axis

The discovery of Fibroblast Growth Factor 23 (FGF23) revolutionised understanding of phosphate homeostasis. FGF23 is produced by osteocytes and acts on the kidney (requiring Klotho co-receptor) to:

1. Inhibit sodium-phosphate cotransporters (NaPi-2a, NaPi-2c) in proximal tubules → phosphaturia
2. Suppress 1-alpha-hydroxylase → ↓ calcitriol production
3. Stimulate 24-hydroxylase → ↑ calcitriol degradation

In XLH, PHEX mutations lead to reduced degradation of FGF23 → excessive FGF23 activity → renal phosphate wasting and inappropriately low/normal vitamin D levels despite hypophosphataemia. New therapies targeting this pathway (e.g., burosumab, an anti-FGF23 monoclonal antibody) have transformed XLH management. [29]

---

4. Clinical Presentation

Rickets (Children)

Rickets typically manifests between 6-24 months (peak bone growth) or during adolescent growth spurts. Presentation depends on severity and duration.

Early/Mild Disease

• Nonspecific symptoms: Irritability, developmental delay, hypotonia
• Growth faltering: Failure to thrive, short stature
• Motor delay: Delayed sitting, crawling, walking
• Increased infection susceptibility: Recurrent respiratory infections

Moderate to Severe Disease

Skeletal Manifestations:

Dental Manifestations:

• Delayed tooth eruption
• Enamel hypoplasia
• Increased caries risk
• Dental abscesses (particularly in XLH)

Neuromuscular Manifestations:

• Hypotonia: "Floppy infant"
• Proximal muscle weakness: Difficulty standing from sitting
• Delayed motor milestones: Late walking (> 18 months)
• Hypocalcaemic seizures: Generalised tonic-clonic seizures (medical emergency)
• Tetany: Carpopedal spasm, laryngospasm
• Stridor: Laryngeal spasm (life-threatening)

Cardiopulmonary Complications:

• Dilated cardiomyopathy: Severe hypocalcaemia
• Respiratory compromise: Severe chest wall deformity, decreased lung compliance
• Recurrent respiratory infections: Impaired immunity

Haematological:

• Anaemia: Often iron-deficiency anaemia (dietary deficiency cluster)

Severe/Neglected Disease

• Pathological fractures: Minimal trauma fractures
• Short stature: Permanent growth impairment if untreated
• Permanent deformity: Requiring corrective osteotomies
• Pelvic deformity: Narrowed pelvic outlet (implications for future childbirth in females) [12,30]

Osteomalacia (Adults)

Osteomalacia often has an insidious onset with vague symptoms, leading to diagnostic delays (average 2-3 years from symptom onset).

Cardinal Symptoms

1. Bone Pain (80-90% of patients)

• Character: Deep, dull, aching pain; diffuse, poorly localised
• Distribution: Hips, lower back, ribs, pelvis, lower limbs
• Exacerbating factors: Weight-bearing, movement
• Relieving factors: Rest (unlike inflammatory arthritis)
• Timing: Often worse at night
• Misdiagnosis: Frequently labelled as fibromyalgia, chronic pain syndrome, somatisation [5,31]

2. Proximal Muscle Weakness (50-70%)

• Myopathic pattern: Difficulty rising from chair, climbing stairs, lifting arms overhead (brushing hair, hanging washing)
• Waddling gait: Wide-based, Trendelenburg-like gait
• Muscle pain: Myalgia, cramps
• Preserved reflexes: Distinguishes from neuropathy
• Rapid reversal with treatment: Diagnostic hallmark [5]

3. Fragility Fractures (30-40%)

• Sites: Vertebral compression fractures, hip, wrist, ribs
• Minimal trauma: Fractures from standing height or less
• Poor healing: Delayed union/non-union

Physical Examination Findings

General Inspection:

• Gait abnormality: Waddling, antalgic gait
• Skeletal deformity: Kyphosis, reduced height
• Muscle wasting: Proximal muscle groups (quadriceps, hip flexors, shoulder girdle)

Specific Signs:

• Bone tenderness: Palpation of sternum, ribs, iliac crests, tibiae elicits pain
• Proximal muscle weakness:
  • Positive Gowers' sign (using hands to "climb up" legs when rising from floor)
  • Inability to rise from squat without arm support
  • Weak shoulder abduction/flexion
• Trendelenburg gait: Hip abductor weakness
• Neuromuscular irritability (severe hypocalcaemia):
  • "Chvostek's sign: Facial muscle twitching on tapping facial nerve"
  • "Trousseau's sign: Carpopedal spasm induced by inflating BP cuff above systolic pressure for 3 minutes (more specific than Chvostek's)"

Biochemical Severity and Symptoms

Atypical Presentations

1. Asymptomatic (Incidental Finding):

• Discovered on routine blood tests: elevated ALP, low vitamin D
• Common in early/mild disease

2. Acute Presentation:

• Hypocalcaemic crisis: Seizures, tetany, altered consciousness, arrhythmias
• Acute fracture: Pathological or insufficiency fracture as presenting feature

3. Renal Osteodystrophy (CKD-MBD):

• Complex bone disease in CKD combining osteomalacia (low vitamin D), secondary hyperparathyroidism (high PTH), and adynamic bone disease
• Vascular calcification (calciphylaxis in severe cases)
• Renal phosphate retention (unlike nutritional osteomalacia) [9]

4. Tumour-Induced Osteomalacia (Oncogenic Osteomalacia):

• Paraneoplastic syndrome from FGF23-secreting mesenchymal tumours
• Profound hypophosphataemia, bone pain, fractures
• Diagnosis: Elevated FGF23, imaging to locate tumour (often small, difficult to find—may require functional imaging with FDG-PET or somatostatin receptor scintigraphy)
• Treatment: Surgical resection curative [28]

---

5. Differential Diagnosis

Osteomalacia and rickets must be distinguished from other metabolic bone diseases, myopathies, and causes of bone pain.

Key Differentials

Clinical Decision-Making: Bone Pain + Elevated ALP

When faced with bone pain and elevated ALP, the key is the calcium and phosphate levels:

1. Low/normal Ca, Low PO4, ↑ ALP, ↑ PTH → Osteomalacia (check vitamin D)
2. High Ca, ↑ ALP, ↑ PTH → Primary hyperparathyroidism
3. Normal Ca, ↑↑ ALP (very high), normal PO4 → Paget's disease (XR shows mixed lytic/sclerotic)
4. High Ca, ↑ ALP, anaemia, renal impairment → Myeloma (check protein electrophoresis)
5. Normal Ca, normal PO4, normal ALP → Not metabolic bone disease (consider fibromyalgia, polymyalgia, myopathy)

---

6. Investigations

Biochemistry: The Diagnostic Cornerstone

The diagnosis of osteomalacia/rickets is primarily biochemical. The classic triad is:

1. Low or low-normal calcium
2. Low phosphate
3. Elevated alkaline phosphatase

First-Line Blood Tests

Critical Point: 25(OH)D is the correct test for vitamin D status, not 1,25(OH)2D (calcitriol). Calcitriol levels are tightly regulated and often normal or even elevated in vitamin D deficiency due to secondary hyperparathyroidism driving 1-alpha-hydroxylase. Requesting calcitriol levels is a common error. [3,32]

Interpretation of Vitamin D Levels

Optimal levels for musculoskeletal health are > 50-75 nmol/L based on PTH suppression studies. [33]

Additional Useful Tests

Biochemical Patterns in Specific Aetiologies

Radiology

Radiographic changes confirm and characterise the disease, but biochemistry makes the diagnosis.

Rickets (Paediatric Imaging)

Plain Radiographs (Wrist, Knee):

• Widening of growth plates (physis): Normally 2-3 mm; widens to 5-10+ mm
• Metaphyseal changes:
  • Cupping: Concave deformity of metaphysis (looks like "cup")
  • "Fraying: Irregular, indistinct metaphyseal margins (loss of sharp zone of provisional calcification)"
  • "Splaying: Widened metaphysis"
• Osteopenia: Generalised reduced bone density
• Coxa vara: Decreased femoral neck-shaft angle
• Bone deformities: Bowing of long bones (tibiae, femora, radii/ulnae)
• Rachitic rosary: Visible on lateral chest X-ray (expansion of anterior rib ends)
• Looser's zones: Rare in children (more common in adults)

Grading Severity (Thacher Radiographic Scoring):

• Grade 1: Minimal metaphyseal changes
• Grade 2: Moderate cupping and fraying
• Grade 3: Severe cupping, fraying, metaphyseal dysplasia [34]

Osteomalacia (Adult Imaging)

Plain Radiographs:

• Looser's zones (pseudofractures): Pathognomonic finding
  • Appear as radiolucent lines perpendicular to cortex
  • Bilateral, symmetrical
  • "Classic sites: Medial femoral neck, pubic rami, ribs (lateral), scapulae (medial border), clavicles"
  • Represent unmineralised osteoid at sites of vascular penetration or stress
  • May progress to complete fractures
• Generalised osteopenia: Reduced bone density (indistinguishable from osteoporosis on XR alone)
• Codfish vertebrae: Biconcave vertebral bodies (compression by intervertebral discs)
• Triradiate pelvis: Protrusio acetabuli (medial migration of acetabulum)
• Bowing deformities: Particularly in long-standing disease
• Fractures: Vertebral compression fractures, fragility fractures

DEXA Scan:

• Low bone mineral density (BMD): T-score often < -2.5 (osteoporotic range)
• Cannot distinguish osteomalacia from osteoporosis: Both show low BMD
• Use: Assess fracture risk, monitor treatment response
• Limitation: Measures quantity, not quality of mineralisation [6,7]

Advanced Imaging (Specialist Centres)

Bone Biopsy (Gold Standard—Rarely Required)

Indications (specialist decision):

• Diagnostic uncertainty despite biochemical/radiological workup
• Suspected coexisting bone pathology (e.g., Paget's disease, malignancy)
• Research purposes

Technique:

• Iliac crest biopsy (trans-iliac)
• Tetracycline double-labelling (given 2 weeks apart pre-biopsy to assess mineralisation rate)

Histological Findings:

• Increased osteoid volume and thickness (> 20 μm; normal less than 12 μm)
• Increased osteoid surface (> 60%; normal less than 35%)
• Decreased mineralisation lag time (time from osteoid deposition to mineralisation)
• Wide osteoid seams: Unmineralised collagen matrix
• Absence of tetracycline uptake (failure of mineralisation)

Not routinely performed due to invasiveness and diagnostic yield from biochemistry/radiology. [35]

---

7. Management

Management centres on correcting vitamin D deficiency, addressing the underlying cause, and preventing complications. Treatment is highly effective, with symptoms often resolving within weeks to months.

Principles of Management

1. Identify and treat the underlying cause
2. Replace vitamin D (with loading then maintenance)
3. Supplement calcium if dietary intake inadequate
4. Monitor biochemistry to ensure resolution and avoid toxicity
5. Address complications (fractures, deformity)
6. Prevent recurrence (long-term supplementation in high-risk groups)

---

Vitamin D Replacement Regimens

The cornerstone of treatment is vitamin D replacement. Choice of preparation depends on renal function and underlying aetiology.

1. Nutritional Vitamin D Deficiency (Normal Renal Function)

Preparation: Cholecalciferol (Vitamin D3) or Ergocalciferol (Vitamin D2)

• D3 is preferred (more bioavailable, longer half-life than D2)

Regimen (NICE CKS, Endocrine Society Guidelines): [36,37]

Clinical Response:

• Bone pain: Improves within 2-4 weeks
• Muscle weakness: Resolves within 4-12 weeks (dramatic improvement)
• Biochemistry: ALP normalises within 6-12 months; PTH within 3-6 months
• Radiological healing: Looser's zones heal over 6-12 months; growth plate changes resolve in 2-6 months in children [38]

2. Malabsorption Syndromes

Higher doses required due to impaired absorption:

• Loading: 50,000 IU daily for 2-4 weeks, then weekly
• Maintenance: 3,000-6,000 IU daily (or higher, titrated to 25(OH)D levels)
• Alternative: Intramuscular cholecalciferol (300,000 IU IM single dose)—useful in severe malabsorption or non-adherence [39]

3. Chronic Kidney Disease (CKD Stage 4-5)

Critical: Standard vitamin D (cholecalciferol/ergocalciferol) is ineffective because the kidney cannot perform 1-alpha-hydroxylation.

Preparation: Activated vitamin D (already hydroxylated at position 1):

• Alfacalcidol (1-alpha-hydroxyvitamin D): Requires 25-hydroxylation in liver (preferred in CKD)
• Calcitriol (1,25-dihydroxyvitamin D): Fully active (no further metabolism needed)

Regimen (KDIGO CKD-MBD Guidelines): [9]

• Alfacalcidol: 0.25-1 mcg daily (titrate based on calcium, phosphate, PTH)
• Calcitriol: 0.25-0.5 mcg daily
• Monitoring: Weekly calcium/phosphate initially (risk of hypercalcaemia/hyperphosphataemia); adjust dose to suppress PTH without causing hypercalcaemia
• Phosphate binders: Often required to control hyperphosphataemia (calcium acetate, sevelamer, lanthanum)
• Paricalcitol/doxercalciferol: Selective VDR agonists (less hypercalcaemic effect)—used in secondary hyperparathyroidism

Complications: Risk of hypercalcaemia and vascular calcification (adynamic bone disease)—requires specialist nephrology management.

4. X-Linked Hypophosphataemic Rickets (XLH)

Not responsive to vitamin D alone. Requires dual therapy:

• Oral phosphate: 1-3 g/day (divided doses, 4-5 times daily)—corrects hypophosphataemia
• Calcitriol: 1-3 mcg/day—enhances intestinal phosphate absorption and suppresses secondary hyperparathyroidism
• Burosumab (anti-FGF23 monoclonal antibody): Revolutionary new treatment for XLH; subcutaneous injection every 2 weeks; superior to conventional therapy (normalises phosphate, improves growth, heals rickets) [29,40]

Monitoring: Risk of nephrocalcinosis (calcium-phosphate precipitation in kidneys)—regular renal ultrasound.

5. Tumour-Induced Osteomalacia (Oncogenic Osteomalacia)

Definitive treatment: Surgical resection of FGF23-secreting tumour—curative, with rapid normalisation of phosphate and resolution of symptoms. [28]

Locating the tumour: Often small, difficult to find—requires:

• Functional imaging: FDG-PET, octreotide scan, 68Ga-DOTATATE PET
• Selective venous sampling for FGF23 (specialist centres)

Medical management (if tumour cannot be located or resected):

• Oral phosphate + calcitriol (as in XLH)
• Burosumab (anti-FGF23 antibody)—effective but very expensive

---

Calcium Supplementation

Indications:

• Dietary calcium intake less than 700 mg/day
• Symptomatic hypocalcaemia
• During vitamin D loading (to prevent hungry bone syndrome)

Dosing:

• Adults: 1,000-1,500 mg elemental calcium daily (divided doses with meals for better absorption)
• Children: 500-1,000 mg daily (age-dependent)

Preparations:

• Calcium carbonate (40% elemental calcium; e.g., Calcichew 500 mg elemental Ca per tablet)—requires acid for absorption (take with meals)
• Calcium citrate (21% elemental calcium)—better absorbed, preferred in achlorhydria/PPI use

Monitoring: Avoid hypercalcaemia (risk with excessive vitamin D + calcium). [36]

---

Monitoring Treatment

Hypercalcaemia risk: Low with standard regimens but higher in:

• Sarcoidosis/granulomatous disease (unregulated 1-alpha-hydroxylase in macrophages)
• Primary hyperparathyroidism (coexisting)
• Excessive vitamin D dosing

---

Management Algorithm

SUSPECTED OSTEOMALACIA / RICKETS
(Bone Pain, Myopathy, Skeletal Deformity, ↑ ALP)
                ↓
CHECK: Ca, PO4, ALP, PTH, 25(OH)D, eGFR
                ↓
CONFIRMED DEFICIENCY
(↓/N Ca, ↓ PO4, ↑ ALP, ↑ PTH, ↓ 25(OH)D)
                ↓
IS RENAL FUNCTION NORMAL (eGFR > 60)?
       ┌────────────┴────────────┐
      YES                       NO (CKD 4-5)
       ↓                         ↓
NUTRITIONAL DEFICIENCY      RENAL OSTEODYSTROPHY
       ↓                         ↓
CHOLECALCIFEROL (D3)        ALFACALCIDOL/CALCITRIOL
       ↓                         ↓
LOADING REGIMEN             NEPHROLOGY REFERRAL
50,000 IU weekly × 6        (Complex management:
       ↓                     Phosphate binders,
MAINTENANCE                 PTH suppression,
800-2,000 IU daily          Vascular calcification risk)
       ↓
CALCIUM if intake less than 700 mg/day
       ↓
MONITOR at 1, 3, 6 months
(Ca, PO4, ALP, PTH, 25(OH)D)
       ↓
ENSURE UNDERLYING CAUSE ADDRESSED
(Coeliac screen, Malabsorption workup)

---

Special Scenarios

Pregnancy and Lactation

• Increased requirements: 1,000-2,000 IU daily maintenance
• Screen high-risk groups: Dark skin, covered dress, poor sunlight exposure
• Benefits: Reduced risk of neonatal hypocalcaemia, improved bone health
• Safety: Vitamin D safe in pregnancy (teratogenicity only at doses > 10,000 IU/day) [41]

Neonates and Infants

• Prevention: All breastfed infants should receive 400 IU vitamin D daily from birth
• Treatment of rickets: 2,000 IU daily for 3 months, then 400-800 IU daily
• Maternal supplementation: Insufficient to prevent infantile rickets; direct infant supplementation required [19]

Elderly/Institutionalised

• High prevalence: 50-70% deficiency in nursing homes
• Falls and fractures: Vitamin D reduces fall risk (improved muscle function) and fracture risk
• Routine supplementation: 800-1,000 IU daily recommended for all > 65 years [17]

Bariatric Surgery Patients

• Lifelong supplementation required: Malabsorption persists indefinitely
• Higher doses: 3,000-6,000 IU daily
• Monitor annually: 25(OH)D, calcium, PTH, bone density
• Consider IM vitamin D: If oral absorption inadequate [42]

---

Surgical Management

Indications for Orthopaedic Intervention

1. Pathological/Insufficiency Fractures:

• Internal fixation as per fracture type
• Optimise vitamin D status pre-operatively if possible (reduces risk of non-union)

2. Severe Skeletal Deformity in Children:

• Timing: After biochemical healing (normalised ALP, PTH) to prevent recurrence
• Procedures: Corrective osteotomies for severe genu varum/valgum, tibial bowing
• Hemiepiphysiodesis: Guided growth using plates/staples in growing children (less invasive than osteotomy)

3. Protrusio Acetabuli (Adults):

• May require total hip arthroplasty in severe cases

Outcomes: Excellent with pre-operative metabolic correction; poor if vitamin D deficiency persists (non-union, recurrent deformity). [43]

---

8. Complications

---

9. Prognosis and Outcomes

Adults (Osteomalacia)

Short-term (Weeks to Months):

• Bone pain: Resolves within 2-6 weeks of treatment in 80-90%
• Proximal myopathy: Dramatic improvement within 4-12 weeks (often the most gratifying response)
• Biochemistry: Calcium/phosphate normalise within 4-8 weeks; ALP falls but may take 6-12 months to normalise

Long-term (Months to Years):

• Looser's zones: Heal radiologically over 6-12 months
• Bone mineral density: Improves significantly over 1-2 years (10-20% increase in BMD)
• Fracture risk: Returns to baseline within 1-2 years
• Quality of life: Marked improvement in pain, function, and well-being

Prognosis: Excellent with treatment and compliance. Recurrence is common if supplementation discontinued in high-risk groups. [38,44]

Children (Rickets)

Early Treatment (Before Age 3-4):

• Skeletal deformities: Almost complete resolution due to bone remodelling capacity in young children
• Growth: Catch-up growth occurs; final height usually normal
• Biochemistry: Normalises within 3-6 months
• Radiological healing: Growth plate changes resolve within 2-6 months

Late Treatment (After Age 4-5):

• Residual deformities: Moderate to severe bowing may persist (especially genu varum/valgum)
• Growth: Some permanent height loss if treatment delayed beyond growth spurts
• Dental complications: Enamel defects persist; increased caries risk lifelong

Prognosis: Excellent if treated early; variable if treatment delayed (may require orthopaedic surgery for deformity correction). [30,34]

Renal Osteodystrophy (CKD-MBD)

Prognosis: Poorer than nutritional osteomalacia due to:

• Persistent hyperphosphataemia despite treatment
• Risk of vascular calcification (accelerated cardiovascular disease)
• Adynamic bone disease (from over-suppression of PTH)
• Complications are leading causes of morbidity/mortality in dialysis patients

Management: Requires specialist nephrology input; kidney transplantation often improves bone disease. [9]

Inherited Disorders (XLH)

Prognosis:

• Burosumab era: Transformative; normalises phosphate, improves growth, heals rickets, improves quality of life
• Conventional therapy (phosphate/calcitriol): Modest efficacy; requires lifelong treatment; high pill burden; risk of nephrocalcinosis
• Untreated: Progressive deformity, short stature, dental abscesses, chronic pain

Outcomes: Now significantly improved with targeted FGF23 inhibition. [29,40]

---

10. Prevention and Screening

Primary Prevention

Public Health Strategies:

1. Vitamin D supplementation in high-risk groups:

   • Infants: 400 IU daily from birth (all breastfed infants)
   • Pregnant/lactating women: 400-1,000 IU daily (higher in dark-skinned populations)
   • Elderly > 65 years: 800-1,000 IU daily
   • Housebound/institutionalised: 800-1,000 IU daily
   • Dark skin in high latitudes: 1,000-2,000 IU daily year-round

2. Food fortification: Mandatory fortification of milk, cereals, margarine (policies vary by country; successful in reducing rickets in USA, Canada, Finland)

3. Sun exposure education:

   • Balanced messaging: 10-15 minutes midday sun exposure (without sunscreen) on arms/legs, 2-3 times weekly sufficient for vitamin D synthesis in fair-skinned individuals (longer for dark skin)
   • Caution: Balance skin cancer risk vs. vitamin D synthesis

Dietary Sources (limited efficacy as sole strategy):

• Oily fish (salmon, mackerel, sardines): 400-1,000 IU per serving
• Egg yolks: 40 IU per yolk
• Fortified foods: Milk (100 IU/cup), cereals (40-100 IU/serving)
• Mushrooms exposed to UV: 400-1,000 IU per serving
• Cod liver oil: 400-1,000 IU per teaspoon (avoid in pregnancy due to vitamin A content) [45]

Screening Recommendations

UK NICE Guidance (CG164, 2014): [46]

• No universal screening for vitamin D deficiency
• Targeted screening in high-risk groups:
  • Dark skin + covered dress + limited sun exposure
  • Malabsorption syndromes (coeliac, IBD, post-bariatric surgery)
  • CKD stage 4-5
  • Chronic liver disease
  • Taking enzyme-inducing drugs (anticonvulsants, rifampicin)
  • Unexplained bone pain, myopathy, elevated ALP

Endocrine Society Guidelines (2011): [37]

• Screening in at-risk populations (not general population)
• Measure 25(OH)D in: CKD, malabsorption, obesity (BMI > 30), pregnant/lactating women in high-risk groups, elderly with falls/fractures

Paediatric Screening:

• Consider in infants/children with:
  • Exclusively breastfed > 6 months without supplementation
  • Maternal vitamin D deficiency
  • Dark skin + high latitude
  • Developmental delay, hypotonia, skeletal deformity

---

11. Key Guidelines and Evidence

Major Society Guidelines

Landmark Evidence

1. The Global Consensus on Nutritional Rickets (Munns et al., 2016) [2]

• Multispecialty international consensus defining rickets, diagnostic criteria, and global prevention strategies
• Highlighted re-emergence of rickets in high-income countries
• Established screening and supplementation protocols for at-risk populations

2. Endocrine Society Clinical Practice Guideline (Holick et al., 2011) [37]

• Defined vitamin D deficiency (less than 50 nmol/L), insufficiency (50-75 nmol/L)
• Evidence-based treatment regimens (loading + maintenance)
• Screening recommendations for at-risk groups

3. Vitamin D and Fracture Prevention (DIPART Collaboration, 2010) [47]

• Meta-analysis of 7 RCTs, 68,500 participants
• 800 IU/day vitamin D + calcium reduced hip fractures by 30% and non-vertebral fractures by 14% in elderly
• Lower doses (less than 400 IU) ineffective

4. Burosumab for XLH (Carpenter et al., 2018) [29]

• Phase 3 RCT: Burosumab (anti-FGF23 antibody) superior to conventional therapy (phosphate + calcitriol)
• Normalised phosphate, healed rickets, improved growth, reduced pain
• Paradigm shift in XLH management

5. Vitamin D Supplementation and Fall Prevention (Bischoff-Ferrari et al., 2009) [48]

• Meta-analysis: Vitamin D ≥700 IU/day reduced falls by 19% in elderly
• Mechanism: Improved muscle strength and balance (VDR expression in muscle)

---

12. Examination Focus

Common Exam Questions (MRCP, MRCPCH)

Question 1: Biochemistry Pattern Recognition

Q: "A 32-year-old South Asian woman presents with bone pain and difficulty climbing stairs. Bloods show: Ca 2.0 mmol/L, PO4 0.6 mmol/L, ALP 450 U/L, PTH 150 ng/L (normal less than 65). What is the most likely diagnosis?"

A: Osteomalacia (vitamin D deficiency). Classic biochemical triad: Low/normal Ca, low PO4, elevated ALP, secondary hyperparathyroidism. Next step: Measure 25(OH)D.

---

Question 2: Radiological Diagnosis

Q: "A 45-year-old woman with chronic bone pain has bilateral radiolucent lines perpendicular to the medial femoral cortex. What is the radiological finding and diagnosis?"

A: Looser's zones (pseudofractures), pathognomonic of osteomalacia. These represent unmineralised osteoid at sites of mechanical stress.

---

Question 3: Treatment in Renal Failure

Q: "A patient with CKD stage 5 on haemodialysis has osteomalacia. Which vitamin D preparation is appropriate?"

A: Alfacalcidol or calcitriol (activated vitamin D). Standard cholecalciferol (D3) is ineffective because the kidney cannot perform 1-alpha-hydroxylation. Do NOT prescribe standard vitamin D supplements.

---

Question 4: Paediatric Rickets

Q: "A 15-month-old infant presents with bowing of legs, widened wrists, and delayed walking. X-ray shows metaphyseal cupping and fraying. What is the diagnosis and first-line treatment?"

A: Nutritional rickets. Treatment: Vitamin D 2,000 IU daily for 3 months, then maintenance 400-800 IU daily. Screen for vitamin D deficiency in mother.

---

Question 5: Differentiating Osteomalacia from Osteoporosis

Q: "How do you distinguish osteomalacia from osteoporosis clinically and biochemically?"

A:

• Osteomalacia: Bone pain (diffuse, chronic), proximal myopathy, elevated ALP, low PO4, low vitamin D. Abnormal biochemistry.
• Osteoporosis: Acute fracture pain (not chronic diffuse pain), normal ALP/Ca/PO4/vitamin D. Normal biochemistry.

---

Viva Points

Viva Point: Opening Statement: "Osteomalacia and rickets are metabolic bone disorders characterised by defective mineralisation of bone matrix due to inadequate calcium and phosphate availability. Rickets occurs in children before epiphyseal closure, affecting growth plates and causing skeletal deformity, whilst osteomalacia occurs in adults after growth plate fusion. The most common cause is vitamin D deficiency, affecting approximately 1 billion people globally, with re-emergence in developed nations due to migration, sun avoidance, and cultural practices."

Key Facts to Mention:

1. Biochemical triad: Low/normal Ca, low PO4, elevated ALP (secondary hyperparathyroidism)
2. Diagnostic test: 25-hydroxyvitamin D (less than 25 nmol/L = severe deficiency)
3. Pathognomonic radiology: Looser's zones (pseudofractures) in osteomalacia; metaphyseal cupping/fraying in rickets
4. Treatment: Cholecalciferol 50,000 IU weekly × 6 weeks (loading), then 800-2,000 IU daily (maintenance). Alfacalcidol in CKD.
5. Clinical pearl: Proximal myopathy ("difficulty climbing stairs") is a hallmark sign, resolves within weeks of treatment.

High-Yield Viva Topics:

• Differentiate osteomalacia from osteoporosis (biochemistry normal in osteoporosis)
• Why standard vitamin D doesn't work in CKD (cannot perform 1-alpha-hydroxylation)
• X-linked hypophosphataemic rickets: Normal calcium, very low phosphate, elevated FGF23
• Management algorithm based on renal function
• Prevention: Infant supplementation (400 IU daily), high-risk groups (dark skin, covered dress, elderly)

---

Common Mistakes (That Fail Candidates)

❌ Requesting 1,25(OH)2D (calcitriol) instead of 25(OH)D to diagnose vitamin D deficiency

• Calcitriol is tightly regulated and often normal/elevated in deficiency (due to secondary hyperparathyroidism driving 1-alpha-hydroxylase). 25(OH)D is the correct test.

❌ Prescribing standard vitamin D (cholecalciferol) in CKD stage 4-5

• Ineffective due to impaired 1-alpha-hydroxylation. Must use alfacalcidol or calcitriol.

❌ Missing proximal myopathy as a key diagnostic feature

• "Difficulty climbing stairs" or "waddling gait" is pathognomonic and resolves rapidly with treatment—a diagnostic clue.

❌ Confusing osteomalacia with osteoporosis

• Osteoporosis: Normal bone composition, low bone mass, normal bloods, acute fracture pain
• Osteomalacia: Abnormal mineralisation, low bone quality, abnormal bloods (↑ ALP, ↓ PO4, ↓ Vit D), chronic bone pain

❌ Failing to check for underlying causes (malabsorption)

• Always screen for coeliac disease (tTG), consider IBD, pancreatic insufficiency, post-bariatric surgery.

❌ Not monitoring for hypercalcaemia during treatment

• Risk of vitamin D toxicity (especially in sarcoidosis, primary hyperparathyroidism). Monitor calcium at 1 month.

---

Model Answers

Q: Describe your approach to a patient presenting with bone pain and proximal muscle weakness

A: "I would approach this systematically. First, I would take a detailed history focusing on risk factors for vitamin D deficiency: ethnicity, sun exposure, dietary intake, cultural dress practices, malabsorption symptoms, and medication history (anticonvulsants). On examination, I would assess for proximal muscle weakness (difficulty rising from a chair, Gowers' sign), skeletal tenderness (ribs, sternum), and signs of neuromuscular irritability (Chvostek's, Trousseau's signs).

My initial investigations would include a bone profile (calcium, phosphate, ALP, PTH) and 25-hydroxyvitamin D. If osteomalacia is confirmed (low/normal Ca, low PO4, elevated ALP, low vitamin D), I would check renal function (eGFR) to guide vitamin D preparation choice.

For nutritional deficiency with normal renal function, I would prescribe cholecalciferol 50,000 IU weekly for 6 weeks (loading), followed by 800-2,000 IU daily maintenance. Calcium supplementation if dietary intake less than 700 mg/day. In CKD stage 4-5, I would use alfacalcidol instead and refer to nephrology.

I would investigate underlying causes: coeliac serology (tTG IgA), consider malabsorption workup if indicated. Monitoring includes calcium at 1 month (risk of hypercalcaemia), then ALP, PTH, and 25(OH)D at 3-6 months to confirm biochemical healing. I would also provide dietary and sun exposure advice and ensure long-term supplementation in high-risk groups to prevent recurrence."

---

Q: How would you counsel a South Asian mother about preventing rickets in her breastfed infant?

A: "I would explain that breast milk, whilst optimal nutrition, contains very little vitamin D. To prevent rickets (soft bones), her baby needs 400 IU vitamin D daily from birth as a supplement (e.g., Healthy Start vitamins). This is especially important for dark-skinned infants in the UK due to limited sunlight exposure.

I would also advise her that she should take 400-1,000 IU vitamin D daily during pregnancy and breastfeeding to ensure her own bone health. I would reassure her that these supplements are safe, inexpensive, and available free on the Healthy Start scheme if eligible.

Additionally, I would provide balanced advice on sun exposure: 10-15 minutes of midday sun on her baby's arms and legs (without sunscreen) 2-3 times weekly in summer is beneficial, but supplementation is still essential, especially in winter months (October-March in the UK). I would stress that vitamin D supplementation should continue throughout childhood."

---

13. References

Primary Sources

1. Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem? J Steroid Biochem Mol Biol. 2014;144 Pt A:138-145. doi:10.1016/j.jsbmb.2013.11.003

2. Munns CF, Shaw N, Kiely M, et al. Global consensus recommendations on prevention and management of nutritional rickets. J Clin Endocrinol Metab. 2016;101(2):394-415. doi:10.1210/jc.2015-2175

3. Carpenter TO, Shaw NJ, Portale AA, et al. Rickets. Nat Rev Dis Primers. 2017;3:17101. doi:10.1038/nrdp.2017.101

4. Bhan A, Rao AD, Rao DS. Osteomalacia as a result of vitamin D deficiency. Endocrinol Metab Clin North Am. 2010;39(2):321-331. doi:10.1016/j.ecl.2010.02.001

5. Glerup H, Mikkelsen K, Poulsen L, et al. Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int. 2000;66(6):419-424. doi:10.1007/s002230010085

6. Milonig KD, Nawrot-Wawrzyniak K. Looser zones: review of imaging findings and differential diagnosis. Skeletal Radiol. 2017;46(6):733-738. doi:10.1007/s00256-017-2616-5

7. Fukumoto S, Ozono K, Michigami T, et al. Pathogenesis and diagnostic criteria for rickets and osteomalacia. J Bone Miner Metab. 2015;33(5):467-473. doi:10.1007/s00774-015-0698-7

8. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289(1):F8-F28. doi:10.1152/ajprenal.00336.2004

9. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001

10. Goldacre M, Hall N, Yeates DGR. Hospitalisation for children with rickets in England: a historical perspective. Lancet. 2014;383(9917):597-598. doi:10.1016/S0140-6736(14)60211-7

11. Thacher TD, Fischer PR, Tebben PJ, et al. Increasing incidence of nutritional rickets: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc. 2013;88(2):176-183. doi:10.1016/j.mayocp.2012.10.018

12. Elder CJ, Bishop NJ. Rickets. Lancet. 2014;383(9929):1665-1676. doi:10.1016/S0140-6736(13)61650-5

13. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281. doi:10.1056/NEJMra070553

14. Ahmed SF, Franey C, McDevitt H, et al. Recent trends and clinical features of childhood vitamin D deficiency presenting to a children's hospital in Glasgow. Arch Dis Child. 2011;96(7):694-696. doi:10.1136/adc.2009.173195

15. Bassil D, Rahme M, Hoteit M, et al. Hypovitaminosis D in the Middle East and North Africa: prevalence, risk factors and impact on outcomes. Dermatoendocrinol. 2013;5(2):274-298. doi:10.4161/derm.25111

16. Roy DK, Berry JL, Pye SR, et al. Vitamin D status and bone mass in UK South Asian women. Bone. 2007;40(1):200-204. doi:10.1016/j.bone.2006.07.004

17. Holick MF, Matsuoka LY, Wortsman J. Age, vitamin D, and solar ultraviolet. Lancet. 1989;2(8671):1104-1105. doi:10.1016/s0140-6736(89)91124-0

18. Lips P. Worldwide status of vitamin D nutrition. J Steroid Biochem Mol Biol. 2010;121(1-2):297-300. doi:10.1016/j.jsbmb.2010.02.021

19. Wagner CL, Greer FR, American Academy of Pediatrics Section on Breastfeeding, American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics. 2008;122(5):1142-1152. doi:10.1542/peds.2008-1862

20. Topal E, Çatalyürekli M, Yildirim ŞA, et al. Vitamin D deficiency in celiac disease: prevalence and predictive factors. Turk J Gastroenterol. 2020;31(1):10-15. doi:10.5152/tjg.2019.18314

21. Hollis BW, Wagner CL. Clinical review: the role of the parent compound vitamin D with respect to metabolism and function: why clinical dose intervals can affect clinical outcomes. J Clin Endocrinol Metab. 2013;98(12):4619-4628. doi:10.1210/jc.2013-2653

22. Hochberg Z. Vitamin D and rickets. Endocr Dev. 2003;6:45-104. doi:10.1159/000072774

23. Thacher TD, Clarke BL. Vitamin D insufficiency. Mayo Clin Proc. 2011;86(1):50-60. doi:10.4065/mcp.2010.0567

24. Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. 2014;21(3):319-329. doi:10.1016/j.chembiol.2013.12.016

25. Jones G, Prosser DE, Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res. 2014;55(1):13-31. doi:10.1194/jlr.R031534

26. Priemel M, von Domarus C, Klatte TO, et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res. 2010;25(2):305-312. doi:10.1359/jbmr.090728

27. Aranow C. Vitamin D and the immune system. J Investig Med. 2011;59(6):881-886. doi:10.2310/JIM.0b013e31821b8755

28. Florenzano P, Gafni RI, Collins MT. Tumor-induced osteomalacia. Bone Rep. 2017;7:90-97. doi:10.1016/j.bonr.2017.09.002

29. Carpenter TO, Whyte MP, Imel EA, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378(21):1987-1998. doi:10.1056/NEJMoa1714641

30. Thacher TD, Fischer PR, Strand MA, et al. Nutritional rickets around the world: causes and future directions. Ann Trop Paediatr. 2006;26(1):1-16. doi:10.1179/146532806X90556

31. Al Faraj S, Al Mutairi K. Vitamin D deficiency and chronic low back pain in Saudi Arabia. Spine (Phila Pa 1976). 2003;28(2):177-179. doi:10.1097/00007632-200301150-00015

32. Nimitphong H, Holick MF. Vitamin D status and sun exposure in southeast Asia. Dermatoendocrinol. 2013;5(1):34-37. doi:10.4161/derm.24054

33. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930. doi:10.1210/jc.2011-0385

34. Thacher TD, Fischer PR, Pettifor JM, et al. Radiographic scoring method for the assessment of the severity of nutritional rickets. J Trop Pediatr. 2000;46(3):132-139. doi:10.1093/tropej/46.3.132

35. Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res. 2011;26(6):1368-1376. doi:10.1002/jbmr.309

36. NICE Clinical Knowledge Summary. Vitamin D deficiency in adults - treatment and prevention. 2020. Available at: https://cks.nice.org.uk/topics/vitamin-d-deficiency-in-adults/

37. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(7):1911-1930. doi:10.1210/jc.2011-0385

38. Priemel M, von Domarus C, Klatte TO, et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res. 2010;25(2):305-312. doi:10.1359/jbmr.090728

39. Romagnoli E, Mascia ML, Cipriani C, et al. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab. 2008;93(8):3015-3020. doi:10.1210/jc.2008-0350

40. Insogna KL, Briot K, Imel EA, et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res. 2018;33(8):1383-1393. doi:10.1002/jbmr.3475

41. De-Regil LM, Palacios C, Lombardo LK, et al. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev. 2016;1:CD008873. doi:10.1002/14651858.CD008873.pub3

42. Mechanick JI, Youdim A, Jones DB, et al. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring). 2013;21 Suppl 1:S1-S27. doi:10.1002/oby.20461

43. Sabharwal S, Zhao C, McClemens E, et al. Correlation of pain and radiographic severity in osteoarthritis results in inconsistent recommendations for total knee arthroplasty. J Arthroplasty. 2013;28(10):1736-1740. doi:10.1016/j.arth.2013.04.044

44. Bergman GJ, Fan T, McFetridge JT, et al. Efficacy of vitamin D3 supplementation in preventing fractures in elderly women: a meta-analysis. Curr Med Res Opin. 2010;26(5):1193-1201. doi:10.1185/03007991003659814

45. Cashman KD, Dowling KG, Škrabáková Z, et al. Vitamin D deficiency in Europe: pandemic? Am J Clin Nutr. 2016;103(4):1033-1044. doi:10.3945/ajcn.115.120873

46. NICE. Vitamin D: supplement use in specific population groups. Public health guideline [PH56]. 2014. Available at: https://www.nice.org.uk/guidance/ph56

47. DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group. Patient level pooled analysis of 68,500 patients from seven major vitamin D fracture trials in US and Europe. BMJ. 2010;340:b5463. doi:10.1136/bmj.b5463

48. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009;339:b3692. doi:10.1136/bmj.b3692

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and refer to the most current guidelines for patient management.